These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27943001)

  • 1.
    Raulinaitis V; Tossavainen H; Aitio O; Seppala R; Permi P
    Biomol NMR Assign; 2017 Apr; 11(1):69-73. PubMed ID: 27943001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and structural characterization of LytU, a unique peptidoglycan endopeptidase from the lysostaphin family.
    Raulinaitis V; Tossavainen H; Aitio O; Juuti JT; Hiramatsu K; Kontinen V; Permi P
    Sci Rep; 2017 Jul; 7(1):6020. PubMed ID: 28729697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus.
    Gründling A; Schneewind O
    J Bacteriol; 2006 Apr; 188(7):2463-72. PubMed ID: 16547033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conserved loop residues-Tyr
    Charoenjotivadhanakul S; Sakdee S; Imtong C; Li HC; Angsuthanasombat C
    Biochem Biophys Res Commun; 2023 Aug; 668():111-117. PubMed ID: 37245291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus.
    Sugai M; Fujiwara T; Ohta K; Komatsuzawa H; Ohara M; Suginaka H
    J Bacteriol; 1997 Jul; 179(13):4311-8. PubMed ID: 9209049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staphylococcus aureus mutants with increased lysostaphin resistance.
    Gründling A; Missiakas DM; Schneewind O
    J Bacteriol; 2006 Sep; 188(17):6286-97. PubMed ID: 16923896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural bases of peptidoglycan recognition by lysostaphin SH3b domain.
    Mitkowski P; Jagielska E; Nowak E; Bujnicki JM; Stefaniak F; Niedziałek D; Bochtler M; Sabała I
    Sci Rep; 2019 Apr; 9(1):5965. PubMed ID: 30979923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and Functional Insights Into Lysostaphin-Substrate Interaction.
    Tossavainen H; Raulinaitis V; Kauppinen L; Pentikäinen U; Maaheimo H; Permi P
    Front Mol Biosci; 2018; 5():60. PubMed ID: 30018958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical shift assignments of the catalytic domain of Staphylococcus aureus LytM.
    Tossavainen H; Pitkänen I; Antenucci L; Thapa C; Permi P
    Biomol NMR Assign; 2024 Jun; 18(1):1-5. PubMed ID: 37914968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysostaphin: Engineering and Potentiation toward Better Applications.
    Zha J; Li J; Su Z; Akimbekov N; Wu X
    J Agric Food Chem; 2022 Sep; 70(37):11441-11457. PubMed ID: 36082619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and characterization of the antibacterial peptidase lysostaphin from Staphylococcus simulans: Adverse influence of Zn
    Chandra Ojha S; Imtong C; Meetum K; Sakdee S; Katzenmeier G; Angsuthanasombat C
    Protein Expr Purif; 2018 Nov; 151():106-112. PubMed ID: 29944958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel S. aureus autolysins and molecular engineering to enhance bacteriolytic activity.
    Osipovitch DC; Therrien S; Griswold KE
    Appl Microbiol Biotechnol; 2015 Aug; 99(15):6315-26. PubMed ID: 25690309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM; Kokai-Kun JF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internally quenched peptides for the study of lysostaphin: An antimicrobial protease that kills Staphylococcus aureus.
    Warfield R; Bardelang P; Saunders H; Chan WC; Penfold C; James R; Thomas NR
    Org Biomol Chem; 2006 Oct; 4(19):3626-38. PubMed ID: 16990938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus.
    DeHart HP; Heath HE; Heath LS; LeBlanc PA; Sloan GL
    Appl Environ Microbiol; 1995 Apr; 61(4):1475-9. PubMed ID: 7747966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-site recognition of Staphylococcus aureus peptidoglycan by lysostaphin SH3b.
    Gonzalez-Delgado LS; Walters-Morgan H; Salamaga B; Robertson AJ; Hounslow AM; Jagielska E; Sabała I; Williamson MP; Lovering AL; Mesnage S
    Nat Chem Biol; 2020 Jan; 16(1):24-30. PubMed ID: 31686030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-staphylococcal activities of lysostaphin and LytM catalytic domain.
    Sabala I; Jonsson IM; Tarkowski A; Bochtler M
    BMC Microbiol; 2012 Jun; 12():97. PubMed ID: 22672475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic expression of mature glycylglycine endopeptidase lysostaphin with an amino terminal hexa-histidine in a soluble and catalytically active form in Escherichia coli.
    Sharma R; Sharma PR; Choudhary ML; Pande A; Khatri GS
    Protein Expr Purif; 2006 Jan; 45(1):206-15. PubMed ID: 16181789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a polypeptide FRET substrate that facilitates study of the antimicrobial protease lysostaphin.
    Bardelang P; Vankemmelbeke M; Zhang Y; Jarvis H; Antoniadou E; Rochette S; Thomas NR; Penfold CN; James R
    Biochem J; 2009 Mar; 418(3):615-24. PubMed ID: 19032148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusion with a cell wall binding domain renders autolysin LytM a potent anti-Staphylococcus aureus agent.
    Osipovitch DC; Griswold KE
    FEMS Microbiol Lett; 2015 Jan; 362(2):1-7. PubMed ID: 25670705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.